Serioss

Products

Excellence In Bone Regeneration

Serioss is a patented, next-generation, silk-protein bone void filler designed for bone regeneration. It is a fully synthetic, biomimetic scaffold made from 100% silk protein, engineered to facilitate predictable bone healing through controlled resorption and superior structural support, for bone defects caused by trauma, infection, cancer, etc. In a first-of-its-kind clinical trial across leading hospitals in India, Serioss has outperformed a leading global player in key bone repair parameters.

Unmet Need

Serioss addresses the unmet need for a synthetic bone void filler with performance like an autograft (patient’s own bone from another location).

Applications of Serioss

Our novel silk protein-based bone void filler is suitable for filling bone cavities caused by –

USPs of Serioss

Our breakthrough osteoconductive bone void filler channels the unique properties of silk protein to offer the following benefits that lead to excellent new bone formation and reduce post-surgical complications –

Optimum Pore Size & Porosity

~40% porosity and ~800 μm pore size enable cell infiltration, vascularization and nutrient exchange.

Excellent Osteoconductivity

Interconnected porous architecture supports osteoblast attachment, migration, proliferation and vascular ingrowth.

Diverse Forms & Sizes

Serioss is available as granules, pellets, wedges and cylinders to conform to a wide range of defect geometries.

Controlled Resorption

Resorbs gradually in sync with new bone formation, enabling progressive load transfer.

Biocompatibility

Non-cytotoxic, non-immunogenic; tested safe and biocompatible per ISO 10993 standards.

Ideal Mechanical Properties

Exhibits mechanical properties comparable to natural bone. Mimics cancellous bone with bone-like compressive strength for defect stability under load.

Product Gallery

Serioss - Osteoconductive bone void filler

Serioss - bone void filler by Serigen Mediproducts

Serioss - Bone void filler with silk protein

Serioss - different forms and shapes for bone regeneration

World's first company to
use Silk Protein for bone regeneration

World's first company to use Silk bone repair

Successful completion of pilot clinical trial with 3-year follow-up

Serioss demonstrated excellent long-term outcomes over a 3-year follow-up study, including a strong safety profile, progressive bone remodeling, complete defect bridging, and optimal anatomical restoration.

Successful completion of pivotal clinical trial with 80 patients in leading hospitals across India

Serioss demonstrated radiological outcomes comparable to or better than TCP, with statistically significant advantages observed in key bone regeneration assessments.

Serioss is non-inferior to the TCP bone void filler
Serioss enables effective new bone formation and functional restoration
Clinical data confirms the safety profile of Serioss
Serioss is suitable across population above 18 years of age for for clinical use in various orthopaedic applications